FDA FOIA Monitor: Special Edition, 2012–2026 Baseline Report
foiadocs.com · Special Edition

FDA FOIA Monitor

2012–2026 Baseline Report

Updated 8/24/26: This baseline now reflects data through July 2026. Wait times shifted in a few doc types since the last revision, most notably FSVP, correspondence, and PMTA, which are now slower than previously reported. The requester landscape figures below have also been refreshed.

65,274 Closed FDA FOIA Requests.
Here Is What They Tell Us.

This special edition establishes the baseline: every FDA FOIA request on file from 2012 through July 2026, analyzed for volume trends, processing times, requester behavior, and document type patterns. 71,077 requests are on file in total; 5,803 remain pending and are not yet closed. The figures below reflect closed requests only unless noted. Bookmark it. Monthly issues will mark movement against this foundation.

65,274 Closed Requests (2012–2026)
71,077 on file · 5,803 still pending
72.7% Full Release Rate
Of closed requests; 1.4% formally denied
25 days Median Processing Time
Avg: 143 days (long tail of complex requests)
2024 Peak Year
13,394 closed · 7,583 closed so far in 2026 (through July)
15.0% Withdrawal Rate
Of closed requests, most due to fees or data found elsewhere
+47.5% Volume Growth, 2020→2024
Before easing back in 2025 as 2024's surge normalized

Processing Times Are Rising. Fast.

2026 median close times, measured year-to-date against 2024. A handful of doc types, FSVP and agency correspondence especially, have gotten dramatically slower; a few, like 510(k) and inspection reports, have actually sped up.

FAERS
15 days
≈ flat vs '24
ANDA
16 days
+3% vs '24
483
██
18 days
+13% vs '24
NDA
███
28 days
+40% vs '24
EIR
███
37 days
↓ 10% vs '24
FSVP
███████
77 days
+492% vs '24
Correspond.
███████
79 days
+163% vs '24
510(k)
███████████████
169 days
↓ 19% vs '24
PMTA
███████████████████████████████████████████████████
559 days
+148% vs '24

Bar length (in block characters) proportional to 2026 YTD median, scaled to PMTA's 559-day median. Trend compares each doc type's 2024 full-year median to its 2026 YTD median.

Practitioner Takeaway If you have a time-sensitive FAERS, ANDA, or 483 request, file now, those remain the fastest tracks at 15 to 18 days. FSVP has seen the steepest jump in the dataset, up nearly 6x from a 13-day 2024 median to 77 days in 2026. PMTA remains the clear outlier at a 559-day median, itself up 148% from 2024's already-slow 225 days.

Who Files FDA FOIA, and How They Do It

Of the 71,077 requests on file, commercial FOIA services dominate volume at 31.0% of all filings, just ahead of individual/citizen requesters at 27.9%. The most striking trend is still news media: outlets grew requests 232% from 2020 to 2025 (305 to 1,013), including 150% growth in 2024 alone (486 to 1,214).

Category Total % of All Median Days Release Rate
Commercial FOIA Services 22,032 31.0% 21 84.3%
Individual / Citizen 19,840 27.9% 27 65.4%
Regulated Industry 15,951 22.5% 24 70.7%
Law Firms 5,865 8.3% 36 64.8%
News / Media
Capitol Forum · Bloomberg · Daily Signal
4,804 6.8% 28 64.6%
Academic / Research 1,905 2.7% 25 70.7%
Advocacy / NGO 523 0.7% 36 65.6%
Government 95 0.1% 4 31.8%
Key Finding Commercial FOIA services have the highest release rate in the dataset at 84.3%, and file in a median of 21 days, the fastest track of any requester type. Government requesters (GAO, federal defenders, congressional offices) file least often and show the lowest release rate at 31.8%. Bloomberg and Capitol Forum continue to drive most of the News/Media growth.

554 GLP-1 Requests Closed Since 2020. 2024 Remains the Peak Year.

GLP-1 FOIA requests grew steadily from 2020 through the 2024 peak, then eased in 2025 as some of that year's filings remain in the pending queue rather than closed. 2026 volume is already running ahead of 2025's pace through July, though a portion of this year's requests are also still open. Of the 554 total, 300 (54%) have been fully released. FAERS reports are the single most-requested doc type (213), followed by agency correspondence (86), NDA review files (74), and ANDA files (41).

2020
3
2021
10
2022
6
2023
██████
42
2024
████████████████████████████████████████
278
2025
█████████████████
115
2026 YTD
██████████████
97

Bar length (in block characters) proportional to count, scaled to 2024's peak of 278. Figures reflect requests closed in each calendar year; 2026 YTD is through July. A meaningful share of 2025- and 2026-filed GLP-1 requests remain pending and will show up in later years' totals as they close.

Notable: Bloomberg's 2024 request for GLP-1 drug communications with food and beverage companies (closed after 705 days with "No Records") signals investigative appetite for supply chain and commercial angle. The Hunterbrook Media request on BPI Labs / Belcher Pharma compounding enforcement released after 695 days.

Top 20 Most-Referenced Companies & Products/Topics

Companies are counted from the Company field (populated on about 25% of requests). Lines marked "(all entities)" combine every spelling variant of that company into one count. Products/topics are counted from a text search of the Title field, which is why some names, like Infant Formula or Fresenius, rank high on the right without appearing on the left.

TOP 20 COMPANIES

1
Catalent (all entities)
258
2
Abbott (all entities)
176
3
CSL Plasma (all entities)
123
4
64
5
56
6
General Mills (all entities)
54
7
51
9
48
10
45
12
43
16
30
17
30
18
29

TOP 20 PRODUCTS / TOPICS

1
389
2
Catalent (CMO)
302
3
Syfovre (pegcetacoplan)
295
4
Semaglutide (GLP-1)
267
5
210
6
199
8
184
9
Lupin (generics)
183
10
171
11
Izervay (avacincaptad pegol)
167
12
Philips (devices)
156
13
Tirzepatide (GLP-1)
148
14
Aurobindo (generics)
142
15
139
17
136
18
Sun Pharma (generics)
134
19
Zydus (generics)
129
20
129
What the Rankings Reveal Pfizer now tops the products list at 389 title mentions, with Catalent (302) and Syfovre (295) close behind. On the companies side, Catalent leads once every entity spelling is combined into one line, at 258 total mentions, followed by Abbott at 176. Several products near the top, like Infant Formula, Fresenius, and Philips, don't appear as named companies at all in the Company field, they only show up through a Title search, which is a reminder that the two lists measure different things.

Watch List: Products With Significant FOIA Activity

Product / Term Category First FOIA Yr All Time 2024 2026 YTD
semaglutide GLP-1 2021 267 159 32
Syfovre Ophthalmology 2023 295 116 2
Catalent CMO / Enforcement 2020 302 39 40
Izervay Ophthalmology 2023 167 108 2
JUUL Tobacco / E-Cig 2020 99 13 2
Capricor Cell Therapy / Rare 2025 13 0 2
ivermectin Policy / COVID-era 2020 61 11 1
naloxone Opioid / OTC 2020 45 9 3

Product Tracker pulls from the Title column. Subscriber access includes the live spreadsheet with formula-based tracking. Add any term to auto-populate counts.

Request Volume by Year

2020
███████████████████████████
9,082
2021
██████████████████████████
8,812
2022
███████████████████████████
8,902
2023
███████████████████████████████
10,496
2024
████████████████████████████████████████
13,394
2025
██████████████████████████████████
11,521
2026 YTD
Through July only, not on the same full-year scale as above
7,583

Bar length (in block characters) proportional to count, scaled to 2024's peak of 13,394. 2026 YTD (7,583 closed through July) is a partial year and shown without a bar; 5,803 more requests across all years remain pending.

A Baseline, Not a Snapshot

This special edition is meant to be evergreen: the full historical picture behind the FDA FOIA Monitor, not a single month's numbers. New subscribers can start here to understand the shape of the dataset before reading a monthly issue.

Monthly issues of the FDA FOIA Monitor track what changed since last month, processing time swings, emerging products and companies, and notable newly-released documents, against this baseline. See the latest monthly issue.
Back to blog